BLFS — BioLife Solutions Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapHigh Flyer

Annual cashflow statement for BioLife Solutions, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	C2020 December 31st	C2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	1.98	-8.91	-140	-66.4	-20.2
Depreciation
Amortisation
Deferred Taxes
Non-Cash Items	3.99	13.8	135	40.2	19.8
Unusual Items
Other Non-Cash Items
Changes in Working Capital	-1.1	-2.26	-14.9	1.47	0.227
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Net Change in Other Assets & Liabilities
Cash from Operating Activities	6.64	-4.59	-8.49	-12.5	8.43
Capital Expenditures	-7.81	-14.8	-13.9	-11.2	-5.59
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	-16.9	1.56	-44.2	29.1	63.9
Acquisition of Business
Sale of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Cash from Investing Activities	-24.7	-13.2	-58.1	17.8	58.3
Financing Cash Flow Items	-0.499	-1.3	-1.84	0.338	-0.377
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	102	-2.78	16.3	10.6	-6.78
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	84	-20.6	-50.4	16	59.9